drug
eluxadoline
Marketedupdated 3mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying eluxadoline
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 7, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (26)
- Mar 14, 2033formulationUS 10188632
- Mar 14, 2033formulationUS 10188632
- Mar 14, 2033formulationUS 11007179
- Mar 14, 2033formulationUS 11007179
- Mar 14, 2033formulationUS 11090291
- Mar 14, 2033formulationUS 11090291
- Mar 14, 2033formulationUS 11160792
- Mar 14, 2033formulationUS 11160792
- Mar 14, 2033formulationUS 11229627
- Mar 14, 2033formulationUS 11229627
- Mar 14, 2033formulationUS 11311516
- Mar 14, 2033formulationUS 11311516
- Mar 14, 2033method-of-use (U-3475)US 11484527
- Mar 14, 2033method-of-use (U-3475)US 12097187
- Mar 14, 2033formulationUS 9675587
- Mar 14, 2033formulationUS 9675587
- May 27, 2029compositionUS 77413562.8y
- May 27, 2029compositionUS 77413562.8y
- Jul 7, 2028compositionUS 86918601.9y
- Jul 7, 2028compositionUS 86918601.9y
- Jul 7, 2028compositionUS 91150911.9y
- Jul 7, 2028compositionUS 91150911.9y
- Jul 7, 2028method-of-use (U-1709)US 93644891.9y
- Jul 7, 2028method-of-use (U-1709)US 93644891.9y
- Jul 7, 2028formulationUS 97891251.9y
- Jul 7, 2028formulationUS 97891251.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 24m ago
Found something off?
comments(0)
5-min edit window · permanent after that